Grand Rapids, MINCT07539311Now EnrollingIRB Ready

Gastrointestinal Cancers Clinical Trial in Grand Rapids, MI

Access cutting-edge gastrointestinal cancers treatment through this clinical trial at a research site in Grand Rapids. Study-provided care at no cost to qualified participants.

Sponsored by Genmab

Quick Self-Assessment

See if you qualify for this Grand Rapids location

Preparing your pre-screening questions…

Expert Care in Grand Rapids

Access gastrointestinal cancers specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related gastrointestinal cancers treatment provided free

Apply for This Grand Rapids Location

Check if you qualify for this gastrointestinal cancers clinical trial in Grand Rapids, MI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Grand Rapids

    Convenient for MI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Grand Rapids site if eligible
  4. 4Begin participation

About This Gastrointestinal Cancers Study in Grand Rapids

This Phase 2 study will be conducted in different countries around the world with up to about 160 participants. The purpose of this study is to evaluate how well Rina-S works against GI cancers. The medication in this study is Rina-S monotherapy (by itself; no other cancer treatments). All participants will receive active drug; no one will be given placebo. Participation in the study will require visits to the study site(s). During site visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity, imaging/X-rays) to monitor whether the study treatment is safe and effective. The duration of the study will be different for every participant, but an average study duration of 22 months is expected for participants. This will include a treatment period (expected to last an average of 12 months), plus data collection periods before and after treatment. Participants will be asked to attend 1 to 5 visits at the study clinic for each cycle (duration of an individual cycle is 21 days). If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open.

Sponsor: Genmab

Who Can Participate

Inclusion Criteria

• All study cohorts
Participant has histologically or cytologically confirmed GI cancer.
Participant has documented metastatic or unresectable disease, not amenable to treatment with curative intent.
Participant has measurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 at baseline.
Participant must have radiological disease progression while on or after receiving the most recent regimen.
Participant has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Participant has life expectancy ≥3 months.
Participant must be able to provide a newly obtained or archival tissue sample.
Participant must have adequate organ and bone marrow function, per laboratory test results prior to Rina-S administration. Key

Exclusion Criteria

(all study cohorts):
Participant has clinically significant non-malignant gastrointestinal disorders, including but not limited to, diarrhea \> grade 1, ulcerative colitis, inflammatory bowel disease.
Participants with recent (up to 4 weeks) history of significant gastrointestinal bleeding, current cancer related ulcerations, fistula, abscess or recent perforation (within 4 to 6 weeks).
Participant has a past or current malignancy other than the inclusion diagnosis before the planned first dose of trial treatment, or any evidence of residual disease from a previously diagnosed malignancy.
Participants with newly identified or known unstable (eg, progressing brain metastases) or symptomatic central nervous system (CNS) metastases or history of carcinomatous meningitis (also known as leptomeningeal disease).
Prior treatment with topoisomerase-1 inhibitor containing antibody-drug conjugate (ADC).
Treatment with an anticancer agent within 28 days prior to the first dose of trial treatment. Note: Other protocol-defined Inclusion and Exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Grand Rapids?

Yes, this clinical trial (NCT07539311) has an active research site in Grand Rapids, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Gastrointestinal Cancers Treatment Options in Grand Rapids, MI

If you're searching for gastrointestinal cancers treatment options in Grand Rapids, MI, this clinical trial (NCT07539311) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Grand Rapids research site is actively enrolling participants for this clinical trial. You'll receive care from experienced gastrointestinal cancers specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all gastrointestinal cancers clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Grand Rapids, MI

See all ankylosing spondylitis clinical trials recruiting in Grand Rapids — not just this study.

Browse Ankylosing Spondylitis Trials in Grand Rapids

Ready to Join in Grand Rapids?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Grand Rapids, MI